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The Journal of Immunology
Absence of MyD88 Results in Enhanced TLR3-Dependent
Phosphorylation of IRF3 and Increased IFN-b and RANTES
Production
Jakub Siednienko,* Thusitha Gajanayake,* Katherine A. Fitzgerald,† Paul Moynagh,*
and Sine´ad M. Miggin*
Toll-like receptors are a group of pattern-recognition receptors that play a crucial role in “danger” recognition and induction of the
innate immune response against bacterial and viral infections. TLR3 has emerged as a key sensor of viral dsRNA, resulting in the
induction of the anti-viral molecule, IFN-b. Thus, a clearer understanding of the biological processes that modulate TLR3
signaling is essential. Previous studies have shown that the TLR adaptor, Mal/TIRAP, an activator of TLR4, inhibits TLR3-
mediated IFN-b induction through a mechanism involving IRF7. In this study, we sought to investigate whether the TLR adaptor,
MyD88, an activator of all TLRs except TLR3, has the ability to modulate TLR3 signaling. Although MyD88 does not significantly
affect TLR3 ligand-induced TNF-a induction, MyD88 negatively regulates TLR3-, but not TLR4-, mediated IFN-b and RANTES
production; this process is mechanistically distinct from that employed by Mal/TIRAP. We show that MyD88 inhibits IKK«-, but
not TBK1-, induced activation of IRF3. In doing so, MyD88 curtails TLR3 ligand-induced IFN-b induction. The present study
shows that while MyD88 activates all TLRs except TLR3, MyD88 also functions as a negative regulator of TLR3. Thus, MyD88 is
essential in restricting TLR3 signaling, thereby protecting the host from unwanted immunopathologies associated with the
excessive production of IFN-b. Our study offers a new role for MyD88 in restricting TLR3 signaling through a hitherto unknown
mechanism whereby MyD88 specifically impairs IKK«-mediated induction of IRF3 and concomitant IFN-b and RANTES
production. The Journal of Immunology, 2011, 186: 2514–2522.
I
nnate immunity is the first line of defense against microbial
pathogens, eliciting the production of inflammatory cytokines
and type I IFNs. A number of classes of pathogen recognition
receptors have evolved to detect pathogens, including the TLRs (1),
the RIG-I–like receptor (RLR) RNA sensors (2), and the recently
described cytosolic DNA receptors (3–5). Of the 10 human TLRs
that have been described, endosomally localized anti-viral TLRs,
namely TLR3, TLR7/8, and TLR9, have evolved to detect dsRNA,
ssRNA, and ssDNA, respectively. Upon activation of the TLRs,
cytosolic TIR domain-containing adaptor proteins are recruited
(1). To date, four activating adaptor proteins have been identifie:
MyD88, MyD88 adaptor-like (Mal)/Toll-IL-1R domain-containing
adaptor protein (TIRAP), Toll/IL-1R domain-containing adapter-
inducing IFN-b (TRIF), and TRIF-related adaptor molecule
(TRAM). Upon initiation of the TLR signaling cascade through
adaptor recruitment via TIR domain interactions, a series of sig-
naling cascades are elicited that ultimately result in the production
of proinflammatory mediators, including TNF-a and IL-6 and the
production of type I IFN, a and b. Despite similarities between the
TLRs in terms of signal transduction pathways, there is specificity
with regard to their adaptor usage (6). MyD88 is the common
downstream adaptor that is recruited by all TLRs except TLR3 (7)
and leads activation of the transcription factor NF-kB (6). Mal is
required for signaling by the LPS receptor TLR4 and the bacterial
lipoprotein receptor TLR2 (8). TRIF mediates TLR3 and TLR4
signaling and is involved in the activation of the transcription fac-
tors IRF3 and IRF7 and consequential expression of type I IFNs (9).
Regarding TRIF, it is the sole adaptor required for TLR3 signaling
(10). Finally, TRAM mediates TLR4 signaling exclusively (9),
acting as a bridging adaptor to recruit TRIF to the TLR4 complex.
Transcriptional activation of the IFN-b gene requires the as-
sembly of a multiprotein complex encompassing the transcription
factors ATF-2/c-Jun, IRF3, IRF7, and NF-kB to form the IFN-b
“enhanceosome.” The enhanceosome elements bind to a nucleo-
some-free region within the IFN-b promoter upstream of the
transcription start site (11). The enhancer itself is divided into four
positive regulatory domains (PRDs) whereby NF-kB binds to the
PRDII element within the IFN-b enhancer region, ATF-2/c-Jun
binds to the PRDIV element and is activated by JNK, and IRF3
and IRF7 bind to the PRDI–III element. Upon activation of TLR3
and TLR4, the IKK-related kinases TNFR-associated factor
(TRAF) family member-associated NF-kB activator binding ki-
nase 1 (TBK1) and IKKε lead to the C-terminal phosphorylation
of IRF3 and IRF7, thereby facilitating their homo- and hetero-
dimerization, nuclear localization, and transcriptional activation of
IFN-b (12).
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Recently, research has been focused toward understanding the
mechanisms that cells employ to curtail TLR signaling and con-
comitant proinflammatory and type I IFN production with a view
to limiting host damage as a consequence of excessive cytokine
production. To this end, a number of molecules that curtail TLR-
mediated IFN-b induction have been identified, including TAG,
Ro52/TRIM21, and SHIP-1 (13–15). Regarding the TLR adaptor
molecules themselves, until quite recently, the physiological role
of these adaptors was considered to be facilitation of TLR acti-
vation and concomitant perpetuation of the signaling cascade.
Recently, studies have been focused toward understanding the role
of the TLR adaptors in noncognate TLR signaling pathways. For
example, it has been shown that the TLR4 adaptor molecule, Mal,
has the ability to limit TLR3-mediated JNK phosphorylation (16).
More recently, we have shown that Mal inhibits TLR3-dependent
IFN-b production through a mechanism involving the inhibition
of IRF7 phosphorylation and nuclear translocation (17). Regarding
the adaptor MyD88, it has been shown that MyD88 negatively re-
gulates TLR3/TRIF-induced corneal inflammation though a mech-
anism involving JNK phosphorylation, but not p38, IRF3, or NF-
kB (18). MyD88 has also been shown to inhibit TLR3-dependent
IL-6 induction, but not IkB degradation or p38 activation in murine
macrophages (16).
To date, the exact mechanisms used by MyD88 to curtail TLR3
signaling and concomitant IFN-b production remain unidentified.
The current study demonstrates that MyD88 negatively regulates
IFN-b cytokine and chemokine production downstream of TLR3,
but not TLR4. We show that MyD88 coimmunoprecipitates with
IRF3 in a TLR ligand-dependent manner. We also show that MyD88
inhibits IKKε-mediated phosphorylation of IRF3, and so our study
identifies MyD88 as a novel negative regulator of TLR3-mediated
IFN-b and CCL5 gene induction.
Materials and Methods
Cell culture and reagents
HEK293 and BEAS-2B cell lines were purchased from European Cell
Culture Collection (Porton Down, U.K.). The HEK293-TLR3 and HEK293-
TLR4 cells were from InvivoGen. HEK293-TLR7 cells were a gift from
Professor Stefan Bauer, University of Marburg. The cells were grown in
DMEMwith GlutaMAX (Life Technologies-BRL) supplemented with 10%
FCS, penicillin-streptomycin, and noromycin and maintained at 37˚C
in a humidified atmosphere of 5% CO2. G418 (200 mg/ml) was added
to maintain HEK293-TLR3, HEK293-TLR4, and HEK293-TLR7 cells.
Highly purified protein-free LPS derived from Escherichia coli strain 011:
B4 was used in all treatments. Naked polyinosinic-polycytidylic acid [poly
(I:C)] and R848 were from InvivoGen. Control and MyD88 inhibitory
peptides were purchased from Imgenex (catalogue no. IMG-2005-1).
MyD88 endoribonuclease-prepared siRNAs (esiRNAs) were purchased
from Sigma-Aldrich. Rhinovirus (RV)1b and RV16 were from Dr. Marc
Hershenson, University of Michigan, and Professor Steve Goodbourn, Uni-
versity of London, respectively.
Expression vectors/recombinant plasmids
The NF-kB-luciferase reporter construct and Flag-TRIF were as described
(9). The plasmid pcDNA3:MyD88-cmyc was a gift from Professor Luke
O’Neill (Trinity College Dublin). The reporter gene contructs IFN-b lu-
ciferase, IFN-b PRDI–III-luciferase, and PRDIV-luciferase were as pre-
viously described (19). The CCL5 reporter gene construct, TBK1-Flag
plasmid, IKKε-Flag plasmid, and IRF3-Flag plasmid were as described
(19). The plasmids encoding the constitutively active forms of RIG-I and
Mda5, namely the CARD domain regions of either RIG-I (RIG-IN) or
Mda5 (Mda-5N) expression plasmids, were gifts from Professor Takashi
Fujita (20).
Sources of macrophages
MyD882/2, TRIF2/2, and mitochondrial antiviral signaling (MAVS)2/2
mice were constructed as described (21–24). MyD882/2 and TRIF2/2
mice were on a C57BL/6 background. MAVS2/2 mice were on a mixed
C57BL/6 and 129 background. All mice were confirmed as being homo-
zygous mutants by PCR genotyping of DNA. All animal protocols used in
this study were approved by the Ethical Committee at the National Uni-
versity of Ireland, Maynooth, and in accordance with the Animals (Sci-
entific Procedures) Act, 1986, U.K. Bone marrow-derived macrophages
(BMDMs) were generated as previously described (16)
First-strand cDNA synthesis
Total RNA was isolated from all types of cells using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions. Thereafter, total
RNA was converted to first-strand cDNA as described (25). Briefly, 1 mg
RNA was incubated with 1 ml random hexamer primers (500 mg/ml) at
70˚C for 5 min. Thereafter, the other reaction components were added in
the following order: 5 ml 5xRT buffer, 1.3 ml 10 mM deoxyribonucleotide
triphosphate, 0.7 ml RNasin (Promega), 1 ml Moloney murine leukemia
virus reverse transcriptase (Promega), and nuclease-free water to a total
volume of 25 ml. The tubes were incubated at 37˚C for 40 min and at 42˚C
for 40 min followed by heating to 80˚C for 5 min. The first-strand cDNA
was stored at 220˚C for up to 1 mo.
Real-time PCR
Total cDNA was used as starting material for real-time RT-PCR quantita-
tion with DyNAmo HS SYBR Green kit (Finnzymes) on a real-time PCR
system (DNA Engine Opticon system; MJ Research). For amplification of
specific genes, the following primers were used; mIFN-b, forward, 59-
GGAGATGACGGAGAAGATGC-39, and reverse, 59-CCCAGTGCTGG-
AGAAATTGT-39; hIFN-b, forward, 59-AACTGCAACCTTTCGAAGCC-
39, and reverse, 59-TGTCGCCTACTACCTGTTGTGC-39; mTNF-a, forward,
59-CATCTTCTCAAAATTCGAGTGACAA-39, and reverse, 59-TGGGA-
GTAGACAAGGTACAACCC-39; mCCL5, forward, 59-GGAGATGAGCT-
AGGATAGAGGG-39, and reverse, 59-TGCCCATTTTCCCAGGACCG-39.
For each mRNA quantification, the housekeeping gene hypoxanthine phos-
phoribosyltransferase (HPRT) was used as a reference point using the fol-
lowing primers: mHPRT forward, 59-CCCTGAAGTACTCATTATAGTC-
AAGGGCAT-39, and reverse, 59-GCTTGCTGGTGAAAAGGACCTCTC-
GAAG-39; hHPRT forward, 59-AGCTTGCTGGTGAAAAGGAC-39, and re-
verse, 59-TTATAGTCAAGGGCATATCC-39. Real-time PCR data were an-
alyzed using 22DDCT method as described (26).
esiRNA transfection
Human BEAS-2B cells were transfected with esiRNA to target the sup-
pression of either MyD88 or control firefly luciferase (FLUC). Briefly, for
each well in a 12-well plate, 200 ng esiRNAwas tranfected using 1 ml N-
TER nanoparticle siRNA transfection system (Sigma-Aldrich, catalogue
no. N2913). After 36 h, efficiency of MyD88 knockdown was assessed
by RT-PCR using the MyD88 forward (59-TCCACAGTGATGCCTACT-
GATGCT-39) and reverse (59-ATGCAGATGAGAGGTGGACCCATT-39)
primers and HPRT forward (59-AGCTTGCTGGTGAAAAGGAC-39) and
reverse (59-TTATAGTCAAGGGCATATCC-39) primers.
Reporter assays
HEK293, HEK293-TLR3, HEK293-TLR4, and HEK293-TLR7 cells (2 3
104 cells/well; 96-well plate) were transfected with 80 ng/well luciferase
reporter gene plasmid for NF-kB, CCL5, IFN-b, pRDΙ–ΙΙΙ, or pRDIV as
previously described (9) and cotransfected with the expression vector
pcDNA3:MyD88, pcDNA3:TRIF, RIG-I, Mda-5, TBK1, or IKKε using
Lipofectamine 2000 (Invitrogen) as described by the manufacturer. In all
cases, 40 ng/well phRL-TK reporter gene was cotransfected to normalize
data for transfection efficiency. After 24 h, cells were stimulated with
ligands as indicated. Thereafter, cell lysates were prepared and reporter
gene activity was measured using the Dual-Luciferase Assay system
(Promega) as described (27). Data were expressed as the mean fold in-
duction6 SD relative to control levels, for a representative experiment from
a minimum of three separate experiments, each performed in triplicate.
Transfection and coimmunoprecipitation
HEK293-TLR3 and HEK293-TLR4 cells (2 3 106 cells/10-cm dish) were
transfected using Lipofectamine 2000 (Invitrogen) with the indicated
plasmids where the total amount of DNA (3 mg/dish) was kept constant.
Twenty-four hours later, cells were stimulated and lysed as described (27).
The indicated Abs (5 mg) were incubated with 40 ml 50% protein G slurry
overnight at 4˚C, washed, followed by the addition of the cell lysates for
2 h. The immune complexes were precipitated, washed, and eluted by the
addition of sample buffer followed by SDS-PAGE and immunoblotting
using the indicated Abs.
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Cytokine analysis
BMDMs (5 3 105 cells/well/48-well plate) were stimulated with the fol-
lowing stimuli: ultrapure LPS, poly(I:C), or R848. After 16 h the cell
supernatants were removed and analyzed for IFN-b release according to
the manufacturer’s recommendations (PBL). TNF-a and CCL5 cytokine
release (PeproTech) were measured as indicated by the manufacturer.
Type I IFN bioassay
Detection of poly(I:C) and LPS-induced bioactive murine type I IFN was
assessed using B16-Blue IFN-a/b cells (InvivoGen), essentially as de-
scribed by the manufacturer.
IRF3/7 nuclear translocation assay
BMDMs were stimulated with poly(I:C) (1 mg/ml) for 0–1 h. Thereafter,
nuclear proteins were isolated using the ProteoJET cytoplasmic and nu-
clear protein extraction kit (Fermentas) as described by the manufacturer.
Thereafter, the nuclear fraction was subjected to immunoblot analysis
using anti-IRF3 (Santa Cruz Biotechnology, sc-9082), anti-IRF7 (Santa
Cruz Biotechnology, (F-1) sc-74471), and anti-nucleolin (Santa Cruz
Biotechnology, C23 (H-6) sc-55486) Abs.
IRF3 immunoblot analysis
Cells were stimulated with ligand as described, and lysates were subjected
to SDS-PAGE followed by immunoblot analysis with an anti-IRF3 (Santa
Biotechnology, sc-9082) and anti–phospho-IRF3 Ab (Cell Signaling Tech-
nology, catalogue no. 4947).
Data analyses
Statistical analysis was carried out using the unpaired Student t test using
SigmaPlot 2001 program. The p values #0.05 were considered to indicate
a statistically significant difference (*p , 0.05; **p , 0.005).
Results
MyD88 negatively regulates IFN-b induction downstream of
TLR3
Given that MyD88 has been shown to negatively regulate TLR3-
mediated JNK activation (18) and that another noncanonical TLR3
adaptor, Mal, has been shown to negatively regulate IFN-b in-
duction (17), we sought to investigate the ability of MyD88 to
modulate TLR3-mediated cytokine production. To this end, we
measured TLR3-mediated cytokine production, namely TNF-a,
Rantes/CCL5, and IFN-b induction by ELISA and quantitative
PCR. Following quantitative real-time RT-PCR measurements, we
demonstrate that whereas stimulation of wild-type (WT) BMDMs
with the TLR3 ligand poly(I:C) resulted in IFN-b gene induc-
tion, a significantly greater induction of IFN-b was evident in
MyD882/2 BMDMs. In contrast, impaired IFN-b gene induction
was evident in MyD882/2 BMDMs compared with WT controls
following LPS stimulation (Fig. 1A). As expected, IFN-b gene
induction was not evident in TRIF-deficient BMDMs following
stimulation with either poly(I:C) or LPS (Fig. 1A). Similarly, in-
creased induction of the IFN-b–dependent chemokine, CCL5, was
evident in MyD882/2 BMDMs when compared with WT cells
following stimulation with poly(I:C), but not with LPS (Fig. 1B).
In contrast, whereas enhanced poly(I:C)-induced TNF-a induction
was not evident in MyD882/2 cells compared with WT cells, a
significant decrease in LPS-mediated TNF-a gene induction was
evident (Fig. 1C).
Next, we sought to investigate the role of MyD88 in the trans-
lational regulation of IFN-b, Rantes, and TNF-a. Thus,MyD882/2,
TRIF2/2, and WT BMDMs were stimulated with the TLR3 ligand
poly(I:C), LPS (TLR4), or R848 (TLR7/8), followed by cytokine
measurement by ELISA. Consistent with the hypothesis that
MyD88 is a negative regulator of TLR3 that mediates IFN-b, poly
(I:C) treatment of MyD882/2 cells increased production of IFN-b
when compared with WT cells (Fig. 1D). Correlating with real-
time PCR data and previous reports (21, 28, 29), LPS- and poly
(I:C)-induced IFN-b production was significantly decreased in
TRIF-deficient BMDMs when compared with WT BMDMs (Fig.
1D). In contrast, increased IFN-b and Rantes/CCL5 induction were
evident in MyD882/2 BMDMs when compared with WT cells
following stimulation with poly(I:C), but not with LPS or R848
(Fig. 1D, 1E). We also show that whereas TNF-a induction was
not significantly different in MyD882/2 cells compared with
WT cells following poly(I:C) stimulation, a significant decrease in
LPS-mediated TNF-a gene induction was evident (Fig. 1F). Al-
though poly(I:C) may be sensed by TLR3, it is also sensed by
the RLR Mda-5, which utilizes the signaling adaptor MAVS (30).
Hence, sensing of poly(I:C) by TLR3 and/or Mda-5 is determined
by the relative expression of either molecule in a given cell, the
subcellular distribution of TLR3, and ligand localization. Given
these factors, it was imperative to assess the relative contribution of
RLRs to poly(I:C)-mediated cytokine production in BMDMs and
to determine the role of MyD88 therein. Correlating with previous
findings (24), comparable induction of IFN-b, CCL5, and TNF-a
was evident in MAVS2/2 BMDMs compared with WT cells fol-
lowing treatment with a MyD88 inhibitory peptide (Fig. 1G–I),
indicating that poly(I:C) mediates its effects through TLR3 rather
than the RLRs in BMDMs. Although it has previously been shown
that poly(I:C)-induced IFN-b induction is Mda5-dependent and
TLR3/Trif-independent (31), our study conclusively shows that
poly(I:C) mediates its effects in a TLR3-dependent mechanism.
The apparent discrepancy between our study and that of Kato et al.
(31) may be attributed to variations in the cell type chosen for
study. Moreover, numerous studies showing that TRIF is essential
for TLR3-mediated IFN-b gene induction (21, 29, 32) add cre-
dence to our finding that poly(I:C) mediates IFN-b gene induction
in murine macrophages in a TRIF-dependent manner and so
implicates TLR3 in the mediation of poly(I:C)-mediated IFN-b
gene induction.
To negate the possibility of species-dependent differences in
MyD88 functionality in the context of TLR3 signaling, the ability
of MyD88 to impair TLR3 signaling in a human system was in-
vestigated. Thus, human lung bronchial epithelial BEAS-2B cells
were chosen as a model, as they express TLR3 and respond well
to poly(I:C), a TLR3 ligand (17). Following the suppression of
MyD88 expression (Fig. 2C), we assessed IFN-b and CCL5 in-
duction following stimulation with poly(I:C). As a control, we
show that exposure of BEAS-2B cells to MyD88 and control
esiRNAs alone does not significantly affect basal IFN-b/CCL5
mRNA expression levels when compared with vehicle-treated
cells (Fig. 2A, 2B). We show that suppression of MyD88 signifi-
cantly enhanced poly(I:C)-induced IFN-b and CCL5 gene in-
duction in human cells (Fig. 2A, 2B). Next, we sought to in-
vestigate the physiological role of MyD88 in the modulation of
virally induced IFN-b induction. To this end, lung epithelial
BEAS-2B cells were treated with two ssRNA viruses that are
known to be immunologically sensed by TLR3 (33), namely RV
serotypes RV1b (a representative of the minor group of RV) and
RV16 (a representative of the major group of RV), in the absence
and presence of MyD88 suppressants followed by assessment
of IFN-b, CCL5, and TNF-a gene induction. It was found that
suppression of MyD88 using either a MyD88 inhibitory peptide or
esiRNA technologies significantly enhanced RV1b- and RV16-
induced IFN-b and CCL5 induction without significantly affect-
ing virally induced TNF-a gene induction when compared with
controls (Fig. 2D–I). Taken together, these data indicate that
MyD88 inhibits TLR3-mediated and virally induced IFN-b and
CCL5 gene induction and suggest that the effects of MyD88 are
both TLR ligand-dependent and specific to the pathway that is
triggered.
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MyD88 negatively regulates TLR3/TRIF-induced IFN-b and
CCL5 promoter activity by inhibiting pathways regulated by
IRF3/7, but not NF-kB or ATF2/c-jun
We next examined the ability of MyD88 to modulate TLR3-
dependent transcription factor activation. To do this, HEK293
cells stably transfected with either TLR3 (HEK293-TLR3), TLR4
(HEK293-TLR4), or TLR7 (HEK293-TLR7) to render them poly
(I:C), LPS, and R848 responsive, respectively, were transiently
transfected with the IFN-b, NF-kB, PRDIV, PRDI–III, and CCL5
reporter gene constructs and increasing amounts of MyD88. Cor-
relating with the analysis of IFN-b gene induction in MyD882/2
BMDMs, we found that although transfection of HEK293-TLR3
cells with MyD88 dose-dependently inhibited poly(I:C)-induced
activation of the IFN-b, PRDI–III, and CCL5 reporter genes
(Fig. 3A), MyD88 did not inhibit, but rather augmented, PRDIV
and NF-kB reporter gene activity (Fig. 3A). In contrast, MyD88 did
not inhibit IFN-b and PRDI–III reporter gene activity in control
HEK293-TLR4 and HEK293-TLR7 cells (Fig. 3B, 3C). As the
adaptor TRIF is critical for TLR3 functionality, we examined the
ability of MyD88 to modulate TRIF signaling. We found that
MyD88 inhibited TRIF-mediated activation of IFN-b, PRDI–III,
and CCL5 reporter gene activity (Fig. 3D–F). As a control, we
found that MyD88 did not inhibit, but rather augmented, IFN-b and
CCL5 reporter gene activity that was driven by the RLRs RIG-I
and Mda5 (Fig. 3D–F). We propose that this effect may be attrib-
uted to the synergistic effect of the RLRs and MyD88 on IFN-b
reporter gene activity. Taken together, these data show that MyD88
exerts a ligand-dependent modulatory effect on TLR activity. Be-
cause MyD88 specifically inhibits the activity of the PRDI–III el-
ement of the IFN-b reporter gene and the CCL5 reporter gene,
which contains an IRF3-dependent ISRE element, we propose
that MyD88 mediates its inhibitory effects on TLR3 through a
mechanism that involves IRF3.
FIGURE 1. Poly(I:C)-induced IFN-b induction is exacerbated in MyD882/2 BMDMs. A–C, Immortalized BMDMs from WT, MyD882/2, and
TRIF2/2 mice were treated with vehicle (control), poly(I:C) (1 mg/ml), or LPS (10 ng/ml) for 4 h. Thereafter, total RNA was isolated, converted to
first-strand cDNA, and used as a template for quantitative real-time RT-PCR as described in Materials and Methods. Quantitative real-time PCR was
used to assay the expression levels of IFN-b (A), CCL5 (B), and TNF-a (C). Experiments were repeated at least three separate times and data
are presented in relative expression units where HPRT was used to normalize all samples. D–F, Immortalized BMDMs from WT, MyD882/2, and
TRIF2/2 mice were treated with poly(I:C) (1 or 10 mg/ml), LPS (10 ng/ml), or R848 (1 mM) for 16 h as indicated. Thereafter, IFN-b (D), RANTES
(E), and TNF-a (F) were measured by ELISA as described in Materials and Methods. Results are representative of at least three independent
experiments performed in triplicate (mean 6 SE). G–I, Immortalized BMDMs from WT, MAVS2/2, and TRIF2/2 mice were pretreated with control
peptide (2; 20 mM) or MyD88 inhibitory peptide (+; 20 mM) for 1 h. Next, cells were treated with poly(I:C) (1 mg/ml) for 4 h. Thereafter, total RNA
was isolated, converted to first-strand cDNA, and used as a template for quantitative real-time RT-PCR as described in Materials and Methods.
Quantitative real-time PCR was used to assay the expression levels of IFN-b (G), CCL5 (H), and TNF-a (I). Experiments were repeated at least three
separate times and data are presented in relative expression units where HPRT was used to normalize all samples and fold increases were determined
relative to vehicle-treated cells.
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MyD88 inhibits IKK«-mediated induction of IRF3
To further explore the mechanism by which MyD88 regulates
IRFs downstream of TLR3/TRIF, HEK293 cells were transfected
with either TBK1 or IKKε and increasing amounts of MyD88.
Given that both TBK1 and IKKε are weak activators of the
IFN-b enhanceosome in HEK293 cells (data not shown), we opted
to cotransfect the cells with TRIF (10 ng) to enhance the signal
output and to aid in the engagement of auxiliary molecules nec-
essary for reporter gene induction. Downstream activation of the
IFN-b, PRDI–III, and CCL5 reporter genes was then examined.
Whereas MyD88 inhibited IKKε-mediated IFN-b, PRDI–III, and
CCL5 reporter gene activity, MyD88 did not inhibit, but rather
enhanced, TBK1-driven reporter gene activity (Fig. 4A–C). Also,
following poly(I:C) stimulation of HEK293-TLR3 cells, MyD88
dose-dependently inhibited IKKε- but not TBK1-driven IFN-b
and PRDI–III reporter gene activity (Fig. 4D). In contrast, fol-
lowing LPS stimulation of HEK293-TLR4 cells, MyD88 dose-
dependently enhanced IKKε and TBK1-driven IFN-b and PRDI–
III reporter gene activity (Fig. 4E). Taken together, these data
strongly suggest that the molecular target for MyD88 on the TLR3
pathway is IKKε and that MyD88 impairs IKKε-induced IRF3
activity and downstream induction of IFN-b.
To test the hypothesis that IKKε-driven IRF3 activity may be
inhibited by MyD88, we tested whether the loss of MyD88 may
affect IRF3 activity. As expected, stimulation of WT BMDMs
with poly(I:C) and LPS enhanced IRF3 phosphorylation indicative
of increased IRF3 activity (Fig. 5A). Furthermore, enhanced poly
(I:C)-, but not LPS-, induced phosphorylation of IRF3 was detected
in MyD882/2 cells compared with WT cells at similar time points
(Fig. 5A). Additionally, whereas nuclear translocation of IRF3
and IRF7 were evident following stimulation of WT BMDMs
with poly(I:C) for 1 h, enhanced nuclear translocation of IRF3,
not IRF7, was detected in MyD882/2 cells compared with WT
cells following poly(I:C) stimulation (Fig. 5B). Additionally, to
show that enhanced nuclear translocation of IRF3 leads to con-
comitant increases in type I IFN in MyD882/2 BMDMs following
poly(I:C) treatment, we opted to quantify bioactive type I IFN in
MyD882/2 and WT BMDMs following stimulation with either
poly(I:C) or LPS. Concomitantly, enhanced production of bioac-
tive type I IFN was evident following stimulation of MyD882/2
FIGURE 2. Suppression of MyD88 expression enhances IFN-b and CCL5 expression. A–C, BEAS-2B cells were pretreated with either control FLUC or
MyD88 esiRNA to target the suppression of MyD88. After 36 h, cells were stimulated with vehicle (control) or poly(I:C) (10 mg/ml) for 4 h and total RNA
was isolated, converted to first-strand cDNA, and used as a template for quantitative real-time RT-PCR as described in Materials and Methods to assay the
expression levels of IFN-b (A), CCL5 (B), or basal MyD88 expression in unstimulated cells (C). The data presented are representative of at least three
independent experiments performed in triplicate (mean 6 SE). D–I, BEAS-2B cells were pretreated for 24 h with either control FLUC or MyD88 esiRNA
to target the suppression of MyD88 as described in Materials and Methods. Alternatively, cells were pretreated with control or MyD88 inhibitory peptide
(20 mM) for 3 h. Next, cells were infected with RV1b or RV16 for 42 h at 33˚C, 5% CO2 in a final concentration of 3% FCS with vehicle serving as
a control. Next, total RNAwas isolated, converted to first-strand cDNA, and used as a template for quantitative real-time RT-PCR as described in Materials
and Methods to assay the expression levels of IFN-b (D, G), CCL5 (E, H), and TNF-a (F, I). The data presented are representative of at least three
independent experiments performed in triplicate (mean 6 SE).
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BMDMs with poly(I:C) when compared with WT (Fig. 5C).
Moreover, whereas coimmunoprecipitation studies have revealed
a weak basal interaction between MyD88 and IRF3 (Fig. 5D, left
and right, lane 3), treatment of HEK293-TLR3 cells with poly
(I:C) enhanced the interaction of MyD88 with IRF3 (Fig. 5D,
left, compare lane 3 to lane 4). In contrast, treatment of HEK293-
TLR4 cells with LPS did not enhance, but rather inhibited, the
interaction of MyD88 with IRF3 (Fig. 5D, right, compare lane 3 to
lane 4). Taken together, these data suggest that the TLR3 ligand-
dependent association of MyD88 with IRF3 may impair the acti-
vation and nuclear translocation of IRF3 and concomitant IFN-b
and CCL5 gene induction.
To further test the hypothesis that curtailment of poly(I:C)-
induced IRF3 activity by MyD88 is mediated through a mecha-
nism involving IKKε, but not a TBK1, we transfected HEK293
cells with IRF3 and either TBK1 or IKKε in the absence and
presence of MyD88. Thereafter, immunoblot analysis was per-
formed using an anti-phosphorylated IRF3 Ab to assess IRF3
phosphorylation status, and increased phosphorylation indicates
enhanced IRF3 activity. As expected, both expression of TBK1
and IKKε induced the phosphorylation of IRF3 (Fig. 5E, lanes 3
and 5). Notably, MyD88 suppressed IKKε-mediated phosphory-
lation of IRF3 (Fig. 5E, lane 6), whereas TBK1-induced phos-
phorylation remained unaffected in the presence of MyD88 (Fig.
5E, lane 4). Our observation that MyD88 suppresses IKKε-
induced activation of IRF3 suggests that MyD88 specifically im-
pairs TLR3:IKKε-induced phosphorylation and translocation of
IRF3 in a ligand-dependent manner. Collectively, these findings
strongly suggest that MyD88 targets IKKε-mediated activation of
IRF3 and that MyD88 inhibits TLR3 signaling by impairing the
phosphorylation and translocation of IRF3, but not IRF7 through
a process involving IKKε.
Discussion
The adaptor protein MyD88 plays a critical role in TLR signaling
whereby it is required for the activation of all TLRs except TLR3
(1). Recently, studies have been directed toward understanding the
role of the TLR adaptors in the negative regulation of noncognate
TLRs. Johnson et al. (18) provided one of the first studies in the
field to highlight a role for TLR adaptors in the negative regulation
of noncognate TLRs whereby they showed that MyD882/2 mice
display an exacerbated inflammatory response following poly(I:C)
stimulation and suppression of MyD88 in human corneal endo-
thelial cells exacerbated TLR3-driven RANTES through a mech-
anism involving JNK (18). Another study has shown that the TLR
adaptor Mal is involved in the negative regulation of TLR3 ligand-
induced JNK phosphorylation in macrophages (16). Importantly,
we have recently shown that Mal plays a novel regulatory role in
TLR3-mediated IFN-b gene induction whereby Mal inhibits
TRIF-mediated activation of IRF7 (17). To date, no study on the
role of MyD88 in the regulation of type I IFN production in re-
sponse to TLR3 ligands has been carried out.
The current study aims to broaden our current understanding of
TLR signaling and the role of TLR adaptors therein. We focused
our attention on MyD88 and sought to explore its role in TLR3-
driven IFN-b gene induction. Using macrophages derived from
MyD882/2 mice, we demonstrate that IFN-b gene expression was
significantly enhanced in the absence of MyD88. This correlates
FIGURE 3. MyD88 negatively regulates TLR3:TRIF-induced activation of IFN-b gene and PRDI–III, but not NF-kB or PRDIV, gene induction. A–C,
HEK293-TLR3, HEK293-TLR4, and HEK293-TLR7 cells were cotransfected with vectors encoding either a reporter gene for the IFN-b promoter, IFN-b
PRDI–III, IFN-b PRDIV, NF-kB, or CCL5 and either empty vector (pcDNA3; 50 ng) or increasing amounts of an expression vector encoding MyD88 (10,
20, 50 ng) as indicated. After 24 h, cells were stimulated with poly(I:C) (25 mg/ml) (A), LPS (1 mg/ml) (B), or R848 (100 nM) (C) for 6 h followed by
harvesting of the cell lysates and assessment of luciferase reporter gene activity. The results presented are representative of at least three independent
experiments. D–F, HEK293 cells were cotransfected with vectors encoding a reporter gene for the full-length IFN-b promoter (D), IFN-b PRDI–III (E), or
CCL5 promoter (F) and either TRIF (20 ng), RIG-I (20 ng), Mda-5 (20 ng), or empty vector (20 ng) and increasing amounts of the expression vector
encoding MyD88 (1, 10, 20 ng) as indicated. After 24 h, cell lysates were harvested followed by assessment of luciferase reporter gene activity. The results
presented are representative of at least three independent experiments.
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with microarray data generated by von Bernuth et al. (34), who
showed an increase in IFN-b mRNA in MyD88-defective indi-
viduals. Similarly, we show that suppression of MyD88 expression
in epithelial cells enhanced TLR3-mediated IFN-b and CCL5 gene
induction, adding further credence to our hypothesis that MyD88
impairs certain signaling pathways mediated through TLR3. In-
terestingly, our finding that IFN-b gene induction mediated by
the ssRNA nonenveloped viruses RV1b and RV16 is enhanced
following the suppression of MyD88 correlates with another
study showing that MyD882/2 mice exhibit enhanced IFN-b
gene induction and enhanced dimeric IRF3 following exposure
to the ssRNA nonenveloped coxsackievirus B3, also a member
of the Picornaviridae family of viruses (35). In this study, we
also demonstrate that the downstream marker of JNK activa-
tion, namely PRDIV reporter gene activity, was not affected by
MyD88. We were also able to confirm that exacerbated RANTES
(CCL5), an important modulator of antiviral defense, is ob-
served in MyD882/2 cells following poly(I:C) stimulation, as
previously shown by others (18). In contrast to TLR3, abolition,
rather than induction, of IFN-b was observed in response to
the TLR4 ligand, LPS, indicating that the inhibitory role of
MyD88 is TLR3-specific rather than a more generalized TRIF-
dependent phenomenon.
To define the molecular mechanisms underlying MyD88-
mediated inhibition of IFN-b and Rantes/CCL5, we examined
the ability of MyD88 to modulate the PRD elements of the IFN-b
gene. We demonstrate that MyD88 impaired poly(I:C)-induced
activation of the PRDI–III element, but not the NF-kB or
PRDIV elements of the IFN-b gene, and that CCL5 reporter gene
activity was also impaired by MyD88 following poly(I:C) stim-
ulation. These data suggested to us that MyD88 somehow mod-
ulated the IRF3/7 transcription factors. Further investigation
revealed that MyD88 specifically impairs IRF3, not IRF7, func-
tionality. Furthermore, this effect was mediated through IKKε,
but not TBK1. Intriguingly, although Mal and MyD88 both have
a negative impact on poly(I:C)-mediated IFN-b gene induction,
MyD88, but not Mal, inhibited poly(I:C)-mediated Rantes pro-
duction. Whereas Mal inhibits TLR3-mediated activation of IRF7,
MyD88 exerts its inhibitory effects through a pathway involving
IKKε:IRF3. Thus, it is clear that the molecular mechanism used
by Mal and MyD88 to curtail innate immune responses emanating
from TLR3 are quite distinct and that our study, which further
defines the molecular role of MyD88 in TLR3 signaling, is clearly
warranted.
The IKK-related kinases IKKε and TBK1 are 64% homolo-
gous, with both molecules containing a catalytic kinase domain,
FIGURE 4. MyD88 negatively regulates IKKε-, but not TBK1-, mediated activation of IFN-b and CCL5 reporter genes. A–C, HEK293 cells were
cotransfected with vectors encoding a reporter gene for the full-length IFN-b promoter (A), IFN-b PRDI–III (B), or CCL5 reporter gene (C) and
cotransfected with TRIF (10 ng) plus TBK1 (10 ng) or TRIF (10 ng) plus IKKε (10 ng) and increasing amounts of the expression vector encoding MyD88
(1, 10, 20 ng) as indicated. After 24 h, cell lysates were harvested followed by assessment of luciferase reporter gene activity. The results presented are
representative of at least three independent experiments. D and E, HEK293-TLR3 and HEK293-TLR4 cells, respectively, were cotransfected with vectors
encoding either a reporter gene for the IFN-b promoter or IFN-b PRDI–III, as indicated, and either empty vector (20 ng), IKKε (20 ng), or TBK1 (20 ng)
and increasing amounts of the expression vector encoding MyD88 (1, 10, 20 ng) as indicated. After 24 h, cells were stimulated with poly(I:C) (25 mg/ml) or
LPS (1 mg/ml) for 6 h followed by harvesting of the cell lysates and assessment of luciferase reporter gene activity. The results presented are representative
of at least three independent experiments.
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a leucine zipper domain, and a helix-loop-helix domain involved
in protein–protein interactions (36). Whereas both TBK-1 and
IKKε can directly phosphorylate IRF3 and IRF7 at key serine
residues within their C-terminal signal-responsive domain (36), it
is becoming increasingly apparent that each of these kinases
exhibits functionally disparate responses to various ligands (36,
37). Regarding the role of these kinases in TLR3 signaling events,
it has been reported that whereas normal IRF3 activation and
IFN-b production was evident in poly(I:C)-treated IKK2/2 em-
bryonic fibroblasts, diminished IRF3 activation and IFN-b pro-
duction was evident in TBK12/2 embryonic fibroblasts. In con-
trast, TBK12/2IKK2/2 double-deficient embryonic fibroblasts
exhibited complete abolition of IRF3 activation (38, 39), indi-
cating that IKKε and TBK1 exhibit different roles in TLR sig-
naling. Despite the apparent differential roles of TBK1 and IKKε
in TLR signaling, minimal ligand-dependent functional analysis
has been undertaken. In this study, we have broadened our un-
derstanding of TLR3 functionality and the differential role of
MyD88 in the modulation of TBK1 and IKKε. The obvious
question is how and why MyD88 specifically blocks IKKε-me-
diated IRF3 activation, but not TBK1-mediated IRF3 activation, in
the context of TLR3. Interestingly, using reporter gene assays, we
have shown that dominant-negative TBK1 does not impair TRIF-
mediated transactivation of IRF3; however, abolition of TRIF-
mediated IRF7 transactivation was evident (data not shown).
Thus, it is plausible to speculate that TBK1 may be redundant in
the functioning of TLR3:TRIF:IRF3-mediated IFN-b and Rantes
production. Studies are currently ongoing in our laboratory to
address this question. Nonetheless, it is clear that MyD88 modu-
lates IKKε-, but not TBK1-, mediated IFN-b and Rantes pro-
duction following poly(I:C) stimulation.
In conclusion, by identifying MyD88 as a critical negative
regulator of TLR3/IKKε-dependent IFN-b and CCL5 induction,
the current study provides insight into the mechanism of TLR3-
dependent signal transduction. MyD88 specifically inhibits TLR3-
dependent type I IFN production, but not TLR4-mediated signal
FIGURE 5. MyD88 blocks IKKε-, but not TBK1-, induced activation of IRF3. A, WT, MyD882/2, and Trif2/2 BMDMs were stimulated with poly(I:C)
(1 mg/ml) or LPS (10 ng/ml) for 0–3 h. Thereafter, immunoblot analysis of whole cell lysates was performed using an anti-phosphorylated IRF3 Ab.
Additionally, immunoblot analysis was performed to confirm the equal expression of IRF3 within each sample. The results presented are representative of at
least three independent experiments. B, WT, MyD882/2, and Trif2/2 BMDMs were stimulated with poly(I:C) (1 mg/ml) for 0, 0.5, or 1 h. Thereafter,
isolation of the nuclear protein fraction was performed as described inMaterials and Methods. Immunoblot analysis was then performed using an anti-IRF3
or an anti-IRF7 Ab. Equal protein loading was confirmed using an anti-nucleolin Ab. The data presented are representative of two independent experiments.
C, WT, MyD882/2, and Trif2/2 BMDMs were stimulated with poly(I:C) (1 mg/ml) or LPS (10 ng/ml) for 0–30 h. Thereafter, the cell-free supernatants
were assessed for bioactive type I IFN as described in Materials and Methods. D, HEK293-TLR3 (left) and HEK293-TLR4 (right) cells were cotransfected
with vectors encoding MyD88-cmyc, IRF3-Flag, or empty vector. After 24 h, cells were then stimulated with poly(I:C) (25 mg/ml) (D, left) or LPS (1 mg/
ml) (D, right) for 90 min. Thereafter, immunoprecipitation (IP) of IRF3-Flag or MyD88-cmyc was performed as indicated. Immunoblot analysis was
performed using anti-Myc Ab. Additionally, immunoblot analysis of whole cell lysates was performed to confirm the equal expression of the indicated
proteins within each sample. The results presented are representative of at least three independent experiments. E, HEK293:TLR3 cells were transfected
with IRF3-Flag (5 ng) and either TBK1-Flag (5 ng) or IKKε-Flag (5 ng) in the absence and presence of MyD88-cmyc (5 ng) as indicated. After 24 h,
immunoblot analysis was performed to detect the presence of phosphor-IRF3 using an anti-phosphorylated IRF3 Ab, total IRF3 using an IRF3 Ab, MyD88-
cmyc using an anti-myc Ab, TBK1 using an anti-Flag Ab, and IKKε using an anti-Flag Ab.
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transduction. We propose that upon TLR3 engagement, MyD88 is
recruited and directly binds to IRF3, thereby inhibiting IKKε-
mediated activation and translocation of IRF3 to the nucleus and
concomitant IFN-b and RANTES production. These results dem-
onstrate that MyD88 negatively regulates TLR3/IKKε-dependent
IFN-b and RANTES production. In conclusion, MyD88 appears
to play a novel major regulatory role in balancing the host inflam-
matory response to viral exposure. It is also clear that manipulation
of the MyD88-regulated pathway to rebalance the host immune
response may represent a novel therapeutic strategy.
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